Qiagen Acquires Point-of-Care Test Maker AmniSure | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen said after the close of the market Thursday that it has acquired AmniSure International, a privately held point-of-care diagnostics firm, for an undisclosed amount.

Boston-based AmniSure sells an assay for determining whether a pregnant woman is suffering rupture of fetal membranes. Qiagen said as many as 30 percent of pregnant women are checked for this condition in clinical settings.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.